Asthma and COPD: Results of Clinical Trials of dual PDE3 and PDE4 inhibitor

Professor Clive Page Director, Sackler institute of Pulmonary Pharmacology Joint Head, Institute of Pharmaceutical Science King's College London 150 Stamford Street Waterloo Campus London SE1 9NHMedicalResearch.com Interview with:
Professor Clive Page
Director, Sackler institute of Pulmonary Pharmacology
Joint Head, Institute of Pharmaceutical Science
King’s College London
150 Stamford Street Waterloo Campus
London SE1 9NH

MedicalResearch.com: What are the main findings of the study?

Prof. Page: RPL 554 was shown to cause bronchodilation and anti-inflammatory activity at the same dose. The drug showed benefit in both patients with COPD and asthma.


MedicalResearch.com: Were any of the findings unexpected?

Prof. Page: Our results were compatible with the activity of RPL 554 to act as an inhibitor of PDE3 (to elicit bronchodilation) and PDE4 (to elicit the anti-inflammatory activity).

MedicalResearch.com What should clinicians and patients take away from your report?

Prof. Page: That we have discovered a new class of bronchodilator that has concomitant anti-inflammatory activity which could provide extra clinical benefit to existing drugs used in the treatment of respiratory diseases such as asthma and COPD.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Prof. Page: Further research in patients with more severe disease and to look at longer term studies to investigate whether the drug could provide an alternative to existing therapy for maintenance treatment

Citation:

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

The Lancet Respiratory Medicine, Early Online Publication, 25 October 2013doi:10.1016/S2213-2600(13)70187-5

No Comments

Sorry, the comment form is closed at this time.